Skip to main content
. 2021 Feb 4;7(2):365–378. doi: 10.1021/acscentsci.0c01670

Figure 4.

Figure 4

Antibody-Targeting Provides High Selectivity for Target Cells. Relative cell viability after 72 h of incubation with or without 10 nM LFN-DTA, and with 10-fold serial dilutions of an IgG or IgG-mPAC conjugate: (A) HER2-positive cells (BT474) with Tmab, Tmab-mPAC, Tmab + mPAC, Tmab-mPACA, or Tmab-LFN-DTA; (B) EGFR-positive cells (A431) with Cmab, Cmab-mPAC, Cmab + mPAC, or Cmab-mPACA; (C) HER2-positive cells (BT474) and HER2-negative cells (BT549) with Tmab-mPAC; (D) EGFR-positive cells (A431) and EGFR-negative cells (Jurkat) with Cmab-mPAC. mPACA represents the mPAC [F427A] variant, which is translocation-deficient. Cell viability was determined by the relative luminescence from a CellTiter-Glo assay, which was normalized to untreated cells. Data represent the mean of three replicate wells ± the standard deviation (±s.d.).